Afterward, the results of CONVINCE phase III clinical trial established icotinib as a front-line treatment for patients with EGFR-sensitizing mutations in lung adenocarcinoma, where the drug prolonged PFS to 11.2 months (compared with 7.9 months associated with chemotherapy HR = 0.61, [P = 0.006]) and also decreased the prevalence of drug-related adverse events by 36.4% compared with that by chemotherapy (54.1% vs. 90.5%, P ​< ​0.001).22 Here, EGFR is linked to lung adenocarcinoma.